Influence of Culture Environment and Mollicutes Contaminations on CD133 Modulation in Cancer Stem Cells by Elisabetta Mariotti et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
19 
Influence of Culture Environment and  
Mollicutes Contaminations on  
CD133 Modulation in Cancer Stem Cells 
Elisabetta Mariotti1, Peppino Mirabelli1,2,  
Francesca D’Alessio1,2, Marica Gemei1,3,  
Rosa Di Noto1,2, Giuliana Fortunato1,2 and Luigi Del Vecchio1,2 
1CEINGE-Biotecnologie Avanzate, Napoli, 
2Dipartimento di Biochimica e Biotecnologie Mediche,  
Università Federico II, Napoli, 
3European School of Molecular Medicine,  
CEINGE-Biotecnologie Avanzate, Napoli, 
Italy 
1. Introduction 
During last years great effort has been addressed towards the research area of cancer stem 
cells (CSC), also called tumour-initiating cells. The intriguing hierarchical model underlying 
the CSC theory, has been extensively described: it implies that only a very small cellular 
compartment within a neoplastic tissue is able to maintain indefinitely tumour growth 
(Bomken, 2010; Sottoriva, 2010). This cellular nucleus is made up of self-renewing stem cells, 
connoted by a more aggressive phenotype, that give rise to all differentiated populations 
forming the tumour (O’Brien, 2010; Zhou, 2009).  
Increasing experimental evidences highlight the key role of CD133 (prominin-1) as CSC 
marker in several human cancers, such as colon carcinoma as well as neural and hepatic 
tumours (Vermeulen et al., 2008).  
The aim of this section is to describe, in details, how environmental factors, culture 
conditions and mycoplasma infections can play a relevant role in CD133 modulation. 
 It was clearly demonstrated that environmental variables can determine a dramatic increase 
of CD133 expression in several human cellular models such as primary culture of tumor 
cells, neurosphere cultures and continuous cancer cell lines. In particular, it has been shown 
that a reduction in oxygen tension, during the culture, both in neurosphere cultures (Bar et 
al., 2010) and in human glioma cell lines (Soeda et al., 2009) can be promptly translated in a 
reversible over-expression of the stemness marker. 
Recently, the involvement of transforming growth factor ┚ (TGF┚) in up-regulation of 
CD133 expression has been clearly demonstrated in human hepatoma, suggesting the 
epigenetic mechanism through TGF┚ influences CD133 modulation (You et al., 2010).  
Additionally, we found evidence that the percentage of CD133+ cells in human colorectal 
cancer cell lines is considerably increased, in reversible manner, in presence of Mycoplasma 
hyorhinis infection (Mariotti et al., 2010). 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
362 
In conclusion, all these observations suggest, the need to maintain CSC cultures in a suitable 
microenvironment, faithful to the hypoxic condition that is “physiologically” found in 
tumors. In addition, it is fundamental to handle cells in good tissue culture practices in 
order to prevent dangerous mycoplasma infections. In this respect, it is essential to 
constantly monitor contamination status of the cultures, by specific detection methods. 
2. Cancer stem cells and CD133 
Stem cells represent the cell population within a tissue, characterized by a longer lifespan 
compared to its more differentiated progeny. This feature makes progenitor cells more 
exposed to genotoxic damage, leading more easily to the induction of oncogenetic 
mutations, and so to cancer development (Pardal, 2003; Reya, 2001).  
The CSC theory implies that cells in tumour have the same hierarchical organization that is 
generally present in the normal tissue counterpart. Therefore, CSC, can be considered the 
population responsible for maintaining and growing the tumour, while other cancer cells 
can only contribute to tumour bulk (Lobo et al., 2007).  
The CSC population within a tumour, due to its “auto-protective” nature, is frequently 
resistant to chemotherapy and radiotherapy and thus it can be responsible for disease 
relapse, or for metastasis generation; for these reasons the targeting and the eradication of 
CSC represent the next frontier in cancer therapy (Dean et al., 2005). 
Currently, there are increasing evidences that CSC, constitute a small compartment of 
distinct cells, characterized by a peculiar phenotype in comparison with other cells that form 
the tumour. Presently, one of the most investigated CSC markers is the CD133. This 
molecule, also called prominin-1, was the first to be identified in the family of prominin 
membrane proteins, both in humans and mice and it was initially classified as a marker of 
primitive haematopoietic and neural stem cells (Mizrak et al. 2008). From a structural point 
of view, CD133 is a cell surface glycoprotein, formed by five trans-membrane domains, two 
cytoplasmic loops, two glycosylated extracellular domains, and a cytoplasmic C-terminal 
domain (Corbeil, 2000; Miraglia, 1997; Yin, 1997). Biological function of CD133 has not yet 
been elucidated, but its peculiar localization suggests its involvement in the organization of 
plasma membrane protrusion (Maw et al., 2000). Recently, it has been confirmed that CD133 
antigen plays a key role as CSC marker in several human cancers, such as colon (O’Brain, 
2007; Ricci-Vitiani, 2007) and hepatocellular (Yin, 2007; Zhang, 2011) carcinoma as well as 
neural (Pallini, 2011; Singh, 2004) and renal (Bruno, 2006; Florek, 2005) tumours. In 
particular, it has been demonstrated the ability of CD133 positive cellular fraction, isolated 
from human tumours, (i) to proliferate in vitro, (ii) to differentiate in vitro and (iii) to develop 
a neoplasia with the original phenotype, when it is transplanted in immunodeficent mice, 
unlike its CD133 negative counterpart (Neuzil, 2007; Singh, 2003).  
In conclusion, CSC can be purified on the basis of their specific cell membrane 
immunophenotypes and in this context, the correct individuation of a peculiar antigenic 
paradigm can become a fundamental target for CSC detection and isolation, aimed at the 
development of future innovative therapeutic strategies.  
3. Culture environment and CD133 modulation sustained by Mollicutes 
The employment of human continuous cell lines is essential for studying biological and 
functional alterations of tumour cells (Hayashi, 2011; van Staveren, 2009). In the previous 
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paragraph, the relevance of CD133 marker as well as its role in detecting and isolating CSC 
from several kinds of human solid tumour has been elucidated. Unfortunately, the correct 
determination of CD133 expression intensity, on cellular surface, can be prejudiced by 
several environmental factors. Our aim is to describe how modifications of culture 
microenvironment, induced by a strong reduction in oxygen tension or growth factors 
exposure or even by Mollicutes infections, can play an important role resulting in a dramatic 
increase of CD133 marker expression. This occurrence has been shown in primary culture of 
tumour cells (Sheehan, 2011; Soeda, 2009), neurosphere cultures (Bar et al., 2010) and in 
several human cellular models such as continuous cancer cell lines. 
 
3.1 Culture environment 
In standard culture conditions, cancer cells are exposed to the ambient oxygen tension, that 
is of about 20%. This percentage is far from the mean oxygen tension generally described for 
in vivo tissues, that ranges from 2% to 9% (Brahimi-Horn, 2007; Studer, 2004). Thus, in 
conventional cell cultures, the oxygenation parameter does not reflect a physiological 
condition and it can be responsible for function alterations, decrease of proliferation and loss 
of stem cells undiffentiated state (Ezashi, 2005; Mohyeldin, 2010).  
These negative effects of hyperoxygenation on stem cells can be explained by the generation 
of dangerous reactive oxygen species, that in turn can cause aberration in DNA structure 
(Busuttil et al., 2003); on the other hand, it has been demonstrated the involvement of 
hypoxia in the activation of the molecular pathways for the regulation of two fundamental 
modulators of stemness, such as Oct-4 and Nocht (Simon & Keith, 2008).  
Interestingly, the hyperoxic condition can reversibly affect the CD133 intensity of expression 
in neurosphere (Bar et al., 2010) and human glioma cell lines cultures (Soeda et al., 2009). In 
particular, human primary tumor neurosphere culture exhibited higher CD133 percentage 
at 3% of oxygen compared to control culture maintained at 20% of oxygen (Platet et al., 
2007); in addition, in hypoxia that is about 1% of oxygen, the human U251MG glioma cells 
showed a time dependent CD133 increase, that was reversed when cells were exposed to 
standard normoxic conditions that is about 21% of oxygen (Griguer et al., 2008). 
These important data have methodological and conceptual implications. Firstly, the 
standard culture condition, under atmospheric oxygen, could represent one of the variables 
involved in the decrease of CD133 cellular phenotype; secondly, CD133 up-regulation could 
be interpreted as an event occurring when tumor cells are exposed to a non-physiological 
condition or rather as a stress response. 
The environment necessary to obtain stem cells cultures requires several cytokines and 
growth factors use. In this regard, it was demonstrated that TGF┚ is involved in the up-
regulation of CD133 expression in the Huh7 continuous cell line, a model for studying 
human hepatocellular carcinoma. Unexpectedly, TGF┚ influenced the marker expression in 
a dose- and time-dependent manner, triggering specific epigenetic events such as the 
inhibition of DNA methyltransferase 1 and DNA methyltransferase3┚ expression, and 
subsequent demethylation of promoter-1 (You et al., 2010). 
Finally, it was also established that epidermal growth factor (EGF) heightened the CD133-
positive subpopulation in primary brain tumor stem cell cultures, determining an increase 
of the stemness marker in a growth factor concentration-related manner (Soeda et al., 
2008). 
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3.2 Mollicutes contaminations 
Mollicutes contamination still remains one of the major problems tightly correlated to the 
manipulation of human continuous cell lines. Mollicutes infections are extremely dangerous 
for two main aspects. Firstly, the contaminations are not evident and they can be revealed 
exclusively by the application of specific detection techniques, such as bioluminescence 
assays (Mariotti et al., 2008), Polymerase Chain Reaction (PCR), by using specific primer 
sequences (Uphof, 2002; Shahhosseiny, 2010) and aerobic and anaerobic microbiological 
agar culture (Uphoff et al., 1992). Secondly, the chronic infections can determine several 
negative consequences on the cultures, including significant morphological changes, 
induction of chromosomal aberrations, modification in protein concentration and alterations 
in DNA and RNA synthesis (Drexler, 2002; Uphoff & Drexler, 2005). In the most serious 
events Mollicutes contaminations lead to the production of unreliable data or to the 
irreversible lost of the culture itself (Derxler & Uphoff, 2002). 
 
 
Fig. 1. Agarose gel with the pattern of restriction fragment length polymorphisms that 
demonstrates the presence of Mycoplasma hyorhinis species in cell culture supernatants 
In this context, our group demonstrated the heavy influence of Mycoplasma hyorhinis 
contamination on CD133 expression in the CSC colon carcinoma compartment (Mariotti et 
al., 2010). In particular, our research project was focused on the isolation and 
characterization of CD133 positive CSC fraction, belonging to the three human colorectal 
cancer continuous cell lines such as GEO, SW480 and HT-29. All cell lines, as suggested by 
good tissue culture practice (UKCCR, 2000), were tested for Mollicutes contaminations by 
two independent methods: the biochemical assay MycoAlert® (Cheong, 2010; Mariotti, 2008) 
and the aerobic and anaerobic microbiological agar culture (Young et al., 2010). All 
supernatants, derived from the three tested cultures, resulted unequivocally Mollicutes 
positive to the above mentioned applied assays. With the aim of establishing the species of 
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the Mollicutes contaminant, we performed on every continuous cell line culture the 
extraction of mycoplasmatic DNA, the amplification by PCR using specific primer 
sequences and the digestion of the amplicons with the restriction endonucleases Asp I, 
Xba I, Hpa II and Hae III. Finally, the analysis of modified restriction fragment length 
polymorphisms (Uphoff & Drexler, 2005) demonstrated that GEO, SW480 and HT-29 cell 
lines were infected by Mycoplasma hyorhinis, as shown in figure 1. 
It is well known that this mycoplasma species is one of the most common infectious agent 
found in continuos cell lines, with a frequency of contamination ranging from 10% to 40%. 
Mycoplasma hyorhinis is a frequent pathogenic agent, isolated from the upper swine 
respiratory tract (Friis & Feenstra, 1994) even if it is thought to derive from bovine source. In 
fact, as swine and cattle are processed through the same abattoirs, the swine strain of 
Mycoplasma hyorhinis may be introduced into bovine serum, commonly used in cell culture 
practice (Drexler & Uphoff, 2000). 
All cell lines for CD133 cytometric expression were then characterized, in confluent culture 
of Mycoplasma hyorhinis GEO, SW480 and HT-29 infected cells, after adequate detachment 
with trypsin/EDTA. The monoclonal antibody used in the study was the anti-CD133/1-PE, 
AC133 clone purchased from Miltenyi Biotec company; an unstained control was prepared 
for each cell line in order to establish the degree of background cellular autofluorescence 
(Figure 2, panel A). All samples were analyzed by a FACSAria flow cytometer with the 
FACS-Diva software.  
As shown in panel B of figure 2, we observed the marked separation of the CD133 positive 
CSC population that was equal to 5.7%, 52.5% and 92.5% in case of GEO, SW480 and HT-29 
mycoplasma infected cell lines, respectively. 
After mycoplasma decontamination, according to the United Kingdom Coordinating 
Committee on Cancer Research guidelines (UKCCR, 2000), CD133 expression was re-
evaluated in the rescue cell lines, in another set of cytometric experiments. As evidenced by 
panel C of figure 2, a noteworthy decrease in CD133 expression occurred, resulting in 2.3%, 
0.2% and 75.6% in case of GEO, SW480 and HT-29, respectively. These interesting data 
confirmed the reversibility of the surprising antigenic variation. 
In order to confirm the exclusive Mycoplasma hyorhinis ability to increase the percentage of 
CD133 positive cells in human colon carcinoma cell lines , we re-infected GEO model by 
aliquots of the same contaminant purchased from the American Type Culture Collection 
(ATCC) international cell bank.  
On the day of the inoculation, the medium was completely replaced with fresh medium 
containing an established dilution of viable Mycoplasma hyorhinis, at a concentration of about 
10 Colony Forming Unit/ml. The infected cells were then incubated at 37°C and 5%CO2 and 
tested with MycoAlert® every seven days. Only in case of positive results they were 
detached with trypsin/EDTA and processed by flow cytometry, for the evaluation of 
CD133. The contamination was detectable only after 3 weeks of culture exposition to the 
specific infective agent.  
This experiment set confirmed that the increase of CD133 expression was closely related to 
Mycoplasma hyorhinis presence in GEO cells, and demonstrated that this “side effect” became 
more severe with the chronicization of the infection. In particular, 3.4%, 4.3%, 26.5% and 
37.2% CD133 positive cells were found on days 21, 28, 49 and 56 post infection respectively, 
wheras 0.3%, 0.7%, 0.8% and 0.9% were detected on days 21, 28, 49 and 56 respectively, in 
Mycoplasma hyorhinis free GEO cells (figure 3 panel C and B).  
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Fig. 2. Cytometric evaluation of CD133 expression in GEO, SW480 and HT-29 cell lines in 
presence of Mycoplasma hyorhinis (panel B), or decontaminated (panel C). Panel A represents 
the negative control 
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Fig. 3. Cytometric evaluation of CD133 expression in mycoplasma free GEO cell lines (panel 
B), and (panel C) infected. Panel A represents the negative control 
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In recent times, the direct Mycoplasma hyorhinis involvement in carcinogenesis of human 
prostatic cells has also been shown (Namiki et al., 2009) as well as its significant role in the 
increase of mesenchyal stromal cells anti-proliferative action in standard lymphocyte 
proliferation assay (Zinocker et al., 2011). 
4. Conclusion 
The aim of this section is to describe the relevant role of environmental factors, culture 
conditions and Mollicutes contamination in CD133-positive CSC compartment. 
 First of all, even thought standard culture condition implies the use of about 20% of oxygen 
tension, this “non-physiological condition” seems to be involved in the decrease of CD133-
positive CSC cellular fraction. It is important to highlight the need to maintain CSC cultures 
in a more suitable microenvironment, faithful to the hypoxic condition that is 
“physiologically” found in tumors. This is desirable in order to work with an in vitro cellular 
model that is, as similar as possible to the original tumor from a biologic and physiologic 
point of view.  
In addition, growth factors as TGF┚ and EGF are able to increase CD133 expression in CSC 
population in a time- and concentration-dependent manner. It is evident that a culture 
medium containing much more appropriate concentrations of cytokines and growth factors 
could be another fundamental tool that enables CSC obtained in vitro to show a phenotype 
which can be better compared to the fresh tumor.  
Finally, it is interesting to notice the effects exerted by Mycoplasma hyorhinis infection on the 
up-regulation of CD133 positive CSC fraction. This occurrence may be justified by: i) the 
influence of the contaminant on monoclonal antibody binding sites, or ii) the selective 
pressure on the CD133-positive CSC fraction, in response to mycoplasma infection. We 
further demonstrated that the extent of CD133 modulation grew with the increase of the 
exposure time to the specific infectious agent.  
We are confident that a tighter control of microenvironmental variables combined with 
prevention measures, detection methods and eradication of Mollicutes infections, will be an 
integral part of the basic panel of CSC manipulation techniques. 
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